Previous 10 | Next 10 |
The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending conditional approval for Akcea Therapeutics' (NASDAQ: AKCA ) Waylivra (volanesorsen) for the treatment of familial chylomicronemia syndrome (FCS), a rare inherited disorder characterized by exce...
BOSTON, Mass. and CARLSBAD, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today that the Committee for Medicinal Products for Human Use (CHM...
BOSTON, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases, today announced the company’s support for Rare Disease Day...
Akcea Therapeutics (AKCA) Q4 2018 Results Earnings Conference Call February 26, 2019, 04:30 PM ET Company Participants Kathleen Gallagher - Vice President of Investor Relations and Corporate Communications Paula Soteropoulos - Chief Executive Officer Sarah Boyce - President Jef...
The following slide deck was published by Akcea Therapeutics in conjunction with their 2018 Q4 earnings Read more ...
Akcea Therapeutics (NASDAQ: AKCA ): Q4 GAAP EPS of -$0.79 misses by $0.06 . More news on: Akcea Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more ...
TEGSEDI™ (inotersen) commercially available in United States, European Union & Canada Achieved Fourth Quarter 2018 TEGSEDI® (inotersen) Global Net Product Revenues of $2.2 Million Conference Call Webcast Tuesday, February 26, 4:30 p.m. ET at www.akceatx.com ...
AAXN , ACAD , AKCA , ARNA , AXGN , BGS , BNFT , CERS , CLGX , CPE , CSGP , CW , DRQ , DVAX , ELF , ENPH , EOG , EVH , FOXF , FRPT , FTR , GWPH , HEI , HPR , HURN , HY , ICFI , IMAX , IMMR , INGN , INN , INSP , JAZZ , JBGS , MASI , MED , MELI , MGRC , M...
Gainers: China Internet Nationwide Financial Services (NASDAQ: CIFS ) +137% . Spark Therapeutics (NASDAQ: ONCE ) +120% . Clementia Pharmaceuticals (NASDAQ: CMTA ) +74% . uniQure N.V. (NASDAQ: QURE ) +30% . Titan Pharmaceuticals (NASDAQ: TTNP ) +27% . CRISPR Therapeutics AG (NASD...
Novartis (NYSE: NVS ) has exercised its option to in-license Akcea Therapeutics' (NASDAQ: AKCA ) AKCEA-APO(a)-L Rx for patients with elevated levels of lipoprotein(a), or Lp(a), and established cardiovascular disease. Novartis will development the antisense drug under the moniker TQJ230. ...
News, Short Squeeze, Breakout and More Instantly...
Akcea Therapeutics Inc. Company Name:
AKCA Stock Symbol:
NASDAQ Market:
Akcea Therapeutics Inc. Website:
Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product PR Newswire BOSTON and CARLSBAD, Calif., Oct. 30, 2020 BOSTON and CARLSBAD, Calif. , Oct. 30, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, In...
Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics Transaction creates a stronger, more efficient company PR Newswire CARLSBAD, Calif., Oct. 12, 2020 CARLSBAD, Calif. , Oct. 12, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS...
NEW YORK, NY / ACCESSWIRE / September 23, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Akcea Therapeutics, Inc. (NASDAQ: AKCA ), relating...